PARCC HEGP
  • fr
  • Rss
Menu
  • Accueil
    • Director’s Introduction
    • Mission and Objectives
    • Activity Reports
  • Research Teams
    • 01-Endothelial Physiopathology and Extracellular vesicules
    • 02-In vivo Imaging Research
    • 03-Genetics to Understand the Physiopathology of Arterial Diseases
    • 04-Integrative Epidemiology of Cardiovascular diseases
    • 05-Immuno-metabolic Mechanisms of Cardiovascular Diseases
    • 06-Regenerative Therapies for Cardiac and Vascular Diseases
    • 07-Cellular, Molecular and Physiological Mechanisms of Heart Failure
    • 08-Kidney and Vascular Signalling: from Development to Disease
    • 09-Vascular Development and Disease
    • 10-Immunotherapy and anti-angiogenic therapy in oncology
    • 11 – Multidimensional Approach in Organ Transplantation
    • 12-Genetic Mechanisms of Aldosterone-Related Disorders – Towards Integrative Precision Medicine
    • 13-Genetics and Metabolism of Rare Cancers
    • All Teams
  • Publications
  • Awards
  • Facilities
    • Small Animal Imaging
    • Molecular Pathology platform
    • Administrative Plateform
    • Histology–Morphology
    • Flow and Image Cytometry
    • In vivo live imaging multiphoton microscopy platform
  • Events
    • Event
    • Conferences
  • Contact
Congratulations to our 2022 PhD graduates. click to know more !

PARCC 2025 - Visite des Tutelles Inserm, Université Paris cité et APHP

Previous Next
  • The PARCC

    The PARCC (Paris Cardiovascular Research Center, Inserm U970) succeeded in bringing together an important critical mass of basic and clinician scientists, who share a vision and common objectives in the field of cardiovascular diseases. PARCC teams are conducting projects, spanning basic molecular and cellular biology to integrated physiology and pathophysiology, biomarkers, genetics and epidemiology, with the goal of understanding, at a more refined and mechanistic level, disease processes in atherosclerosis, angiogenesis, hypertension, heart failure and sudden cardiac death, and also at the interface between cardiology and oncology. They are developing novel diagnostic and therapeutic strategies. Translational research is an integral part of the mission of the PARCC, in close connection with clinical laboratories and departments of the HEGP hospital.

    The PARCC is part of the Université de Paris Cité and of the Institut des sciences cardiovasculaires de l’université de Paris

     

     

    More
  • Recent publications

    From Team 7 (Hulot)

    Novel Cardiokine GDF3 Predicts Adverse Fibrotic Remodeling After Myocardial Infarction . Circulation. 2023

    From Team 5 (Ait-Oufella)

    JAK2V617F mutation drives vascular resident macrophages toward a pathogenic phenotype and promotes dissecting aortic aneurysm.Nat Commun. 2022
    .

    From Team 12 (Zennaro)

    Machine learning for classification of hypertension subtypes using multi-omics: A multi-centre, retrospective, data-driven study. EBioMedicine. 2022

    .

    From Team 9 (Eichmann)

    Conserved meningeal lymphatic drainage circuits in mice and humans. J Exp Med. 2022

    Endothelial Unc5B controls blood-brain barrier integrity. Nat Commun. 2022

     

    Follow us on Twitter @parcc_inserm

    More Publications
  • Directory

    Find a PhD student, a researcher …

    JOIN THE PARCC

    Team 02 is recruiting a PhD student to work on Therapeutic targets of Takotsubo disease. See details in English or in French

    Team 08 is recruiting a post-doctoral fellow to work on cell metabolism in kidney inflammation. More.

    PAPER of the WEEK

    More
  • The PARCC against COVID-19 -news

    See the actions of PARCC’s reaesrchers against #COVID-19

    More
  • Seminars

  • EVENT-NEWS

    See the recent Awards from PARCC’s members

     

    More
  • CONTACT US

    If you want to join us, do not hesitate to upload your CV !

    Upload your CV
  • Glossary
  • Sitemap
  • Find us
  • Terms of use